Compare alternative providers
Alternatives to T2D.com
T2D.com grades C (53/100), #516 of 541 on our scorecard. Start with a featured alternative, then explore providers with similar listed prices and treatment options. Compare their scores and terms below.
You're comparing against
T2D.com →Featured alternative
CoreAge Rx scores 89.5/100. Check the price conditions and care terms against T2D.com.
Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
More options to compare
Push Health is a large US telehealth platform that routes brand-name GLP-1 prescriptions (Ozempic, Zepbound, Mounjaro) through a 55,000+ pharmacy network.
Enhance MD pairs compounded injections with advertised lab testing and care; its four-week supply and 48-week longer plan require a different budget from calendar-month pricing.
Compounded semaglutide and tirzepatide injections advertised at $89/$129 monthly for new patients, with a named medical practice and three possible pharmacies; confirm the continuing price because homepage and terms differ.
Sunlight advertises low flat monthly rates and now names its pharmacy network. Its public pages leave enough uncertainty about the selected payment and shipping timeline that the final plan needs a closer look.
Sprout advertises four-week compounded injection plans and separate annual prepayments; confirm the selected bill, pharmacy handoff and cancellation date.
FDAWarning letter issued to Sprout Health Partners LLC dba Sprout Health in September 2025. See the FDA warning-letter database.
The 6 alternatives above offer other options to compare with T2D.com. Every provider we grade — all 541 of them — is scored on the same six factors: browse every graded provider.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.